Table 1 Immunological repertoire obtained prior to the onset of anti-IL1B therapy evidencing multiple immune defects (relevant alterations shown in bold)
From: Immunological repertoire linked to PSTPIP1-associated myeloid-related inflammatory (PAMI) syndrome
Immunological Profile | Index Patient Before anti-IL1 (%) | Age Matched Reference Range | Mother untreated (%) | Age Matched Reference Range |
|---|---|---|---|---|
CD3+ | 38,9 | 66.2 (57.1-72.7) | 81 | 75.1 56.8-84.1 |
CD4+ | 22,6 | 37.7 (27.7-46.3) | 36,5 | 40.7 26.9-55.5 |
CD8+ | 70,7 | 21.9 (15.7-33.8) | 58 | 27.2 13.3-41.5 |
CD4+ naive | 23,9 | 70.30 (46.14-84.40) | 16,6 | 32,7 (20,9-49,1) |
CD4+ TCM | 10,8 | 26.40 (13.88-48.12) | 32 | 33 (20,8-45,6) |
CD4+ TEM | 5,41 | 2,8 (0.94-6.46) | 11,4 | 25,1 (13,9-33,6) |
CD4+ TEMRA | 1,59 | 0.2 (0.00-1.36) | 1,4 | 4,9 (2-10,3) |
CD19+ | 21,3 | 19,3 (13.3-26.7) | 9,16 | 12 (5.9-20.6) |
CD3-CD16+CD56+(NK) | 1,2 | 7,3 (7,8-16,1) | 3,34 | 8.2 (2.8-24.1) |
CD3+HLA-DR+ | 43,5 | NR | 48,7 | NR |
CD20+CD27+(LB mem) | 27,9 | NR | 29,1 | NR |
CD3+TCRabCD4-CD8- | 2,83 | Total Lymphocytes (<1,5%) | 2,01 | Total Lymphocytes (<1,5%) |
7,54 | CD3+(<2,5%) | NM | CD3+(<2,5%) | |
CD3+B220+ | 31,7 | Total Lymphocytes (NR) | 15,8 | Total Lymphocytes (NR) |